Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study links walking fatigue to higher fall risk in MS patients

NCT ID NCT07524556

Knowledge-focused Sponsor: Ibrahim Ahmad Elmongy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study looks at how walking fatigability—getting tired while walking—changes the way people with multiple sclerosis walk and increases their risk of falling. Researchers will compare two groups of 62 participants: those who experience walking fatigue and those who don't. By measuring gait patterns and fall risk, the study aims to provide insights for future rehabilitation strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help design better rehabilitation programs to reduce fall risk in people with multiple sclerosis.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. Results may not apply to all MS patients, and the small size limits general conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Sixty-two RRMS will be recruited in this study from multiple sclerosis specialized clinic in the Neurology department, Faculty of Medicine, Alexandria University. The patients will be diagnosed and referred to by a neurologist participants aged from 20 to 40 years with a confirmed diagnosis of multiple sclerosis (based on McDonald criteria). Ambulatory for at least 6 minutes, without the use of assistive devices.EDSS score between 2.0 and 5.0.no relapse within 1 month prior to participation

Ages

20 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sixty-two RRMS patients from both sexes. * Aged from 20 to 40 years with a confirmed diagnosis of multiple sclerosis (based on McDonald criteria). * Ambulatory for at least 6 minutes, without the use of assistive devices. * EDSS score between 2.0 and 5.0. * no relapse within 1 month prior to participation Exclusion Criteria: * The presence of other neurological or orthopaedic conditions that could affect gait or balance. * Severe cognitive impairment (as determined by clinical history or physician report). * Active MS relapses or corticosteroid treatment within the last 30 days. * Visual or vestibular impairments that significantly interfere with gait or postural control. * Diabetic patients will be excluded as this will interfere with balance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • multiple sclerosis specialized clinic in the Neurology department, Faculty of Medicine, Alexandria University.

    Alexandria, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.